
EMA recommends extension of trastuzumab deruxtecan
The At its November 2022 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines for Human Use (EMA) Renewal recommended for Trastuzumab deruxtecan (Enhertu, Daiichi Sankyo Europe GmbH): The antibody-drug conjugate directed against HER2 will also be indicated as monotherapy for the treatment of adult patients with advanced HER2-positive gastric […]